Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where M.M. Couttenye is active.

Publication


Featured researches published by M.M. Couttenye.


Vaccine | 1993

Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients

A.F. Lefebure; Gert A. Verpooten; M.M. Couttenye; M. E. De Broe

In renal transplant patients hepatitis B infection is associated with a higher morbidity and mortality. Therefore, we investigated the immunogenicity of an enhanced vaccination scheme with a recombinant DNA hepatitis B vaccine in renal allograft recipients. Injections of 40 micrograms were given at months 0, 1, 2 and 6. Conversion rate (anti-HBS antibody titre > 10 mIU ml-1) was only 36%. On the other hand, in patients vaccinated before transplantation, a booster injection of 40 micrograms was highly successful, resulting in a rise of antibody titre > 10 mIU ml-1 in 86%. In view of the poor vaccination results after transplantation, we strongly recommend hepatitis B vaccination prior to transplantation.


Nephron | 1993

Oxidative Injury to Erythrocytes, Cell Rigidity and Splenic Hemolysis in Hemodialyzed Patients before and during Erythropoietin Treatment

P. Zachée; Augustin Ferrant; R. Daelemans; L. Coolen; W. Goossens; Rl. Lins; M.M. Couttenye; M. E. De Broe; M. A. Boogaerts

The oxidative injury to erythrocytes, red blood cell (RBC) rigidity and splenic hemolysis was assayed in 17 chronically hemodialyzed patients before and during recombinant erythropoietin (EPO) treatment. When a stable hematocrit between 30 and 35% had been established for at least 4 months, a statistically significant increase in RBC volume, hemoglobin concentration, hematocrit, reticulocyte count, and several RBC enzymes (2,3-diphosphoglycerate, glucose 6-phosphate dehydrogenase, pyruvate kinase, hexokinase) was noted. This indicated significant RBC rejuvenation under the influence of EPO. However, no significant improvement in the RBC oxidative sensitivity, RBC deformability, splenic RBC volume, slow mixing splenic RBC volume, and the intrasplenic RBC transit time could be disclosed. These data confirm the existence of an extra-erythrocytic factor in uremic plasma, which is partly responsible for a reduced RBC life span in hemodialysis patients despite EPO treatment.


Clinical Toxicology | 2004

Unusual D‐Lactic Acid Acidosis from Propylene Glycol Metabolism in Overdose

Philippe G. Jorens; Hendrik E. Demey; Paul Schepens; Vera Coucke; Gert A. Verpooten; M.M. Couttenye; Viviane Van Hoof

Objective: To report a case of D‐lactic acid acidosis owing to massive oral ingestion of propylene glycol. Case Report: A 72‐year old man with known congestive failure was admitted to the ICU with encephalopathy. Twelve hours prior to admission he had erroneously ingested a large amount of propylene glycol (PG). The laboratory revealed high anion gap (anion gap = 27 meq/l) acidosis (arterial pH = 7.16) and an increased osmolal gap. Toxicological analysis revealed a low serum propylene glycol level. Biochemical analysis indicated that very high amounts of D‐lactic acid (up to 110 mmol/l), but not of the usual type of L‐lactic acid, were responsible for the metabolic acidosis. Hemodialysis was initiated and associated with a decline of both the acidosis and D‐lactic acid levels. The patient regained conciousness. Conclusion: Ingestion of massive doses of propylene glycol, previously not reported as a cause of D‐lactic acidosis, should be added to the differential diagnosis of this rare condition.


Nephron | 1987

Functional Acute Renal Failure in a Patient with Carcinoid Syndrome

M.M. Couttenye; G. A. Verpooten; R. Daelemans; M. E. De Broe

Acute renal failure occurred in a patient with a carcinoid syndrome whenever he developed a flushing episode. Renal biopsy performed during one of these oliguric episodes did not reveal any lesions which could explain this reversible form of renal insufficiency. Urinary indices were not conclusive. Alteration of intrarenal hemodynamics by vasoactive compounds is proposed to be the causative mechanism of this relapsing acute oliguric renal failure.


Nephrology Dialysis Transplantation | 1996

Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients

M.M. Couttenye; Patrick C. D'Haese; V O Van Hoof; E. Lemoniatou; William G. Goodman; G. A. Verpooten; M. E. De Broe


Clinical Chemistry | 1999

Aluminum, Iron, Lead, Cadmium, Copper, Zinc, Chromium, Magnesium, Strontium, and Calcium Content in Bone of End-Stage Renal Failure Patients

Patrick C. D’Haese; M.M. Couttenye; Ludwig V. Lamberts; Monique Elseviers; William G. Goodman; Iris Schrooten; Walter Cabrera; Marc E. De Broe


Nephrology Dialysis Transplantation | 2004

Re-evaluation and modification of the Stuivenberg Hospital Acute Renal Failure (SHARF) scoring system for the prognosis of acute renal failure: an independent multicentre, prospective study

Robert L. Lins; Monique Elseviers; R. Daelemans; Paul Arnouts; J.M. Billiouw; M.M. Couttenye; Eric Gheuens; P. Rogiers; R.J. Rutsaert; P. Van der Niepen; M. E. De Broe


Nephrology Dialysis Transplantation | 1995

Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload

Patrick C. D'Haese; M.M. Couttenye; William G. Goodman; E. Lemoniatou; Panagiotis N. Digenis; I. Sotornik; A. Fagalde; R. S. Barsoum; Ludwig V. Lamberts; M. E. De Broe


Nephrology Dialysis Transplantation | 1997

High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population.

M.M. Couttenye; Patrick C. D'Haese; J T Deng; V O Van Hoof; G. A. Verpooten; M. E. De Broe


Nephrology Dialysis Transplantation | 1996

Diagnosis and treatment of aluminium bone disease

Patrick C. D'Haese; M.M. Couttenye; M. E. De Broe

Collaboration


Dive into the M.M. Couttenye's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

G. A. Verpooten

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge